Charles L. Ingalls

Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2

Allan Wissner, Heidi L. Fraser, Charles L. Ingalls et al. · Bioorganic & Medicinal Chemistry · 2007 · 75 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as Covalent-Binding, Irreversible Inhibitors of the Kinase Domain of Vascular Endothelial Growth Factor Receptor-2

Allan Wissner, M. Brawner Floyd, Bernard D. Johnson et al. · Journal of Medicinal Chemistry · 2005 · 57 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Enantiopure 2,3-Dihydro-4-pyridones as Synthetic Intermediates:  A Concise Asymmetric Synthesis of (+)-Allopumiliotoxin 267A

Daniel L. Comins, Shenlin Huang, Cheryl L. McArdle et al. · Organic Letters · 2001 · 57 citations

Pharmacy, Chemistry, Medicinal Chemistry +5

The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1)

Thomas Nittoli, Russell G. Dushin, Charles L. Ingalls et al. · European Journal of Medicinal Chemistry · 2009 · 25 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity

Christoph W. Zapf, Jonathan D. Bloom, Jamie L. McBean et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 24 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13